Electrolytic transdermal delivery of polypeptides
First Claim
1. A transdermal patch for delivering at least one drug directly to the bloodstream of the patient comprising in combination:
- (a) an active ingredient comprising at least one polypeptide having from three to 20 peptide units selected from the group consisting of vasopressin, lypressin, atriopeptin, oxytocin, desmopressin, a dynorphin, leuprolide, an angiotensin, and mixtures thereof contained in a drug reservoir, and(b) electrolytic means for transdermal transport of the polypeptide characterized by a current density from about 0.5 microampere/cm2 to about 1 milliampere/cm2,whereby the skin of the patient is neither irritated nor erythematized.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention comprises in combination:
(a) a polypeptide having from about three to about 20 peptide units in aqueous solution or suspension, and
(b) an electrolytic device for transdermal transport of the polypeptide to the bloodstrem of the patient.
It may be useful to enhance the transdermal delivery of the polypeptide by adding an aqueous cosolute/cosolvent with negative Setschenow constants.
The electrolytic device preferably comprises a hydrophilic reservoir containing a supply of the aqueous polypeptide solution or suspension, an electric battery, two extended contacts, and optionally a semipermeable membrane between the reservoir and the patient'"'"'s skin.
Representative polypeptides include oxytocin, angiotensin I, II, and III, substance P, vasopressin, lypressin, desmopressin, leuprolide acetate, antripeptin, and the like.
103 Citations
19 Claims
-
1. A transdermal patch for delivering at least one drug directly to the bloodstream of the patient comprising in combination:
-
(a) an active ingredient comprising at least one polypeptide having from three to 20 peptide units selected from the group consisting of vasopressin, lypressin, atriopeptin, oxytocin, desmopressin, a dynorphin, leuprolide, an angiotensin, and mixtures thereof contained in a drug reservoir, and (b) electrolytic means for transdermal transport of the polypeptide characterized by a current density from about 0.5 microampere/cm2 to about 1 milliampere/cm2, whereby the skin of the patient is neither irritated nor erythematized. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
-
-
14. A transdermal patch for delivering at least one drug directly to the bloodstream of the patient comprising in combination:
-
(a) an active ingredient comprising at least one nonionic polypeptide having from three to 20 peptide units contained in a drug reservoir, and (b) electrolytic means for transdermal transport of the nonionic polypeptide characterized by a current density from about 0.5 microampere/cm2 to about 1 milliampere/cm2, whereby the skin of the patient is neither irritated nor erythematized. - View Dependent Claims (15, 16, 17, 18, 19)
-
Specification